DotLab has completed a $10 million Series A financing, with proceeds set to go toward additional development of its non-invasive diagnostic test for endometriosis, called DotEndo. [DotLab]

DotLab, the San Francisco personalized women’s health company developing a non-invasive diagnostic test for endometriosis, said this week it has completed a $10 million Series A financing.

“DotLab plans to use its Series A financing to further clinical validation, expand market access, and continue to grow our team in the pursuit of our goals,” CEO Heather Bowerman said in a statement.

DotLab is developing a physician-ordered endometriosis test designed to measure disease-specific biomarkers present in body fluids such as blood or saliva, in order to confirm the presence of active endometriosis disease. The test can be used across all stages of disease, regardless of hormonal or menstrual cycle variables, according to the company.

DotLab also asserts that its diagnostic—called DotEndo—offers a more accurate and much easier alternative to laparoscopic surgery under general anesthesia, or medical imaging.

Last year, DotLab announced the start of a longitudinal clinical validation study with investigators at Yale School of Medicine, specifically evaluating the performance of DotEndo compared with laparoscopy in patients with and without endometriosis across multiple clinical cohorts.

A proof-of-concept study published last year in Reproductive Sciences showed that levels of specific microRNA biomarkers in DotEndo reverted to normal levels following treatment and corresponded with the extent of disease. The study also found that the test had potential to also be used to monitor disease progression and response to therapy.

CooperSurgical led the financing, which included participation by individual investors from Tiger Global Management and Luxor Capital Group, as well as the law firm Wilson Sonsini Goodrich & Rosati.

“We’re thrilled to continue our mission to transform #womenshealth via #personalizedmedicine!” the company tweeted on Monday.

CooperSurgical is the business unit of The Cooper Companies, and offers over 600 products and services used primarily by obstetricians and gynecologists, with a focus on healthcare for women, babies, and families that includes medical devices, and fertility, and genomics.

Headquartered in Pleasanton, CA, publicly-traded Cooper Companies operates through CooperSurgical and vision care unit CooperVision. Cooper employs more than 12,000 people and sells products in over 100 countries worldwide.

“CooperSurgical brings significant operational resources and the opportunity to build upon partnerships with health systems to become a leading brand in women’s health. Our shared goal is to make DotLab’s endometriosis test widely accessible,” Bowerman added.

Also of Interest